小袁
Lv4
445 积分
2022-06-06 加入
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
10天前
已关闭
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
10天前
已完结
-
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
11天前
已完结
-
Current developments in gastric cancer: from molecular profiling to treatment strategy
13天前
已完结
-
疼痛评估量表应用的中国专家共识(2020版)
16天前
已完结
-
Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases
19天前
已完结
-
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
26天前
已完结
-
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
1个月前
已完结
-
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
1个月前
已完结
-
TP53 共突变对驱动基因阳性肺癌靶向治疗疗效的影响及对策
1个月前
已完结